Printer Friendly

SETH RUDNICK, M.D., ELECTED CHAIRMAN OF THE BOARD AND THOMAS WIGGANS ELECTED PRESIDENT OF CYTOTHERAPEUTICS

 PROVIDENCE, R.I., March 31 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) announced that Seth Rudnick, M.D., president and chief executive officer of the company since February 1991 has been elected chairman of the board and he remains chief executive officer of CytoTherapeutics. Thomas G. Wiggans, who has served as executive vice president and chief operating officer since February 1992 has been elected president of CytoTherapeutics. Wiggans will continue as chief operating officer and chief financial officer of the company.
 "With the recent acceleration of our product development programs toward human clinical trials, Tom's marketing experience in high-growth companies and innovative health care products will be instrumental in guiding our products from the clinic to commercialization," commented Seth Rudnick, M.D., chairman and chief executive officer of CytoTherapeutics. "These management changes reflect the extraordinary growth of the company in the past year," said Rudnick.
 In March 1992, the company completed its initial public offering that raised $22.5 million to fund its research and development programs through 1994. CytoTherapeutics also completed a 12,000 square foot pilot manufacturing plant in October 1992, which is capable of producing clinical-grade implants for upcoming human clinical trials. Results from preclinical studies in each of the company's product development areas have also shown promising results in 1992. Because of accelerated development in its product for the treatment of severe, chronic pain, the company plans to begin human clinical trials of its CereCRIB(tm) implant in 1993.
 "As we validate our technology in human clinical trials, a key challenge we face is to select the most appropriate applications to develop internally ourselves and determine those areas in which we can maximize the technology by partnerships and collaborations with others," said Tom Wiggans, president and chief operating officer. "It is very exciting to guide our first product toward commercialization and to apply our broad cell-encapsulation technology to new therapeutic areas," he added.
 Prior to joining Cytotherapeutics, Rudnick was senior vice president of the R. W. Johnson Pharmaceutical Research Institute in New Brunswick, N.J., a subsidiary of Johnson & Johnson, Inc. He has also served as vice president of biotechnology product development at Ortho Pharmaceutical Corporation in Raritan, N.J., also a Johnson & Johnson subsidiary. Previously, he was senior vice president for pharmaceutical development at Biogen, Inc.
 Wiggans' career includes five years with Eli Lilly and more than 10 years with the Ares-Serono Group. He was general manager of Serono's U.S. subsidiary from 1985 to 1990, and served most recently as general manager of Serono Laboratories U.K.
 Cytotherapeutics is a leader in the research and development of novel approaches to the delivery of biologically active therapeutic substances to treat severe, chronic diseases. The company is developing a new class of therapeutic products based on its core technology of membrane-encapsulated living cells, which can be implanted into patients directly at the site where they are needed to supply critical biomolecules. CytoTherapeutics' CNS (Central Nervous System) products in development include its CereCRIB(tm) implant, for the treatment of severe, chronic pain, and its NeuroCRIB(tm) implant for the treatment of Parkinson's disease, in addition to its Type I diabetes product in development, EndoCRIB(tm).
 -0- 3/31/93
 /CONTACT: Thomas G. Wiggans, 401-272-3310 ext. 2152 or Elizabeth Razee, ext. 2132 of CytoTherapeutics/
 (CTII)


CO: Cytotherapeutics, Inc. ST: Rhode Island IN: MTC SU: PER

DJ -- NE001 -- 1386 03/31/93 09:22 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:564
Previous Article:KLM ARRIVES IN CINCINNATI AREA, JOINS NORTHWEST TO OFFER TRAVELERS GLOBAL ROUTE NETWORK
Next Article:BRADLEES ELECTS PATRICIA M. POMERLEAU TO BOARD OF DIRECTORS
Topics:


Related Articles
DR. EDWIN CADMAN JOINS BOARD AT CYTOTHERAPEUTICS
NDMA ELECTS BOARD AND OFFICERS
PATRICK AEBISCHER, M.D., Ph.D., JOINS BOARD AT CYTOTHERAPEUTICS
CYTOTHERAPEUTICS INVESTIGATOR AWARDED INTERNATIONAL GRANT TO FUND ONGOING CLINICAL RESEARCH IN ALS
PETER K. SIMON JOINS BOARD AT CYTOTHERAPEUTICS
CYTOTHERAPEUTICS ELECTS SANDRA NUSINOFF LEHRMAN, M.D., PRESIDENT AND CHIEF OPERATING OFFICER
Abbott Announces New Top Management Team

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters